[Neuroimmunological diseases: update].
During the past 10 to 20 years, disease modifying drugs have been introduced into clinical practice relating to neuroimmunological diseases such as multiple sclerosis, myasthenia gravis, and Guillain-Barré syndrome. Based on the mechanism of each disease, therapies are currently being developed that target crucial molecules involved in the disease process. Monoclonal antibodies, such as natalizumab against VLA-4 and alemtuzumab against CD52 antibody, have been found to be very effective for reducing relapse rates and for preventing disease progression in multiple sclerosis. However, molecular-targeted therapy may disrupt the immune balance of patients and unexpectedly induce other autoimmune diseases or opportunistic infections. Therefore, to overcome intractable neuroimmunological diseases utilizing molecular-targeted therapies, future research needs deeper insights into the mechanism of each disease along with close observations of clinical courses.
Department of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University.
Jun-ichi
J
Kira
D000818:Animals; D020274:Autoimmune Diseases of the Nervous System / Q000188:drug therapy / Q000276:immunology; D006801:Humans